In the phase 3 study (NCT03370913), a single 6 × 1013 vg/kg valoctocogene roxaparvovec infusion was administered to 134 adult males with severe hemophilia A (FVIII ≤ 1 IU/dL) on FVIII prophylaxis (negative for FVIII inhibitors) [63]. Here, F8 is linked to hemophilia A.